Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial (BNOEF)
PR Newswire ADELAIDE, Australia, Feb. 22, 2021 BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure
Read more